Journal of Alzheimer’s Disease 30 (2012) 745–749 DOI 10.3233/JAD-2012-112123 IOS Press 745 Short Communication Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on Donepezil Efficacy in Alzheimer’s Disease Patients Diego Albani a,∗,1 , Filippo Martinelli Boneschi b,1 , Gloria Biella a , Giacomo Giacalone b , Sara Lupoli b , Francesca Clerici c , Luisa Benussi d , Roberta Ghidoni e , Daniela Galimberti f , Rosanna Squitti g,h , Stefania Mariani h , Annamaria Confaloni i , Giuseppe Bruno j , Claudio Mariani c , Elio Scarpini f , Giuliano Binetti d , Giuseppe Magnani k , Massimo Franceschi l and Gianluigi Forloni a a Department of Neuroscience, “Mario Negri” Institute for Pharmacological Research, Milan, Italy b INSPE, San Raffaele Scientific Institute, Milan, Italy c Centre for Research and Treatment on Cognitive Dysfunction, Neurology Unit, Luigi Sacco Hospital, University of Milan, Milan, Italy d NeuroBioGen Lab-Memory Clinic, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy e Proteomics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy f Department of Neurological Sciences, “Dino Ferrari” Center, University of Milan, “Fondazione C` a Granda, IRCCS Ospedale Policlinico”, Milan, Italy g Department of Neuroscience, AFaR – Fatebenefratelli Hospital, Isola Tiberina, Rome, Italy h Department of Neurology, “Campus Biomedico” University, Rome, Italy i Istituto Superiore di Sanit` a, Department of Cell Biology and Neurosciences, Rome, Italy j Department of Neurology and Psychiatry, University of Rome “Sapienza”, Rome, Italy k Department of Neurology, Clinical Neurophysiology and Neurorehabilitation, San Raffaele Scientific Institute, Milan, Italy l Department of Neurology, IRCCS Multimedica, Milan, Italy Handling Associate Editor: Patrizia Mecocci Accepted 11 March 2012 Abstract. Alzheimer’s disease (AD) is a neurodegenerative disorder often treated with donepezil, an acetylcholinesterase inhibitor. Response to donepezil is variable, probably based on patients’ genetic background in donepezil metabolizing enzymes, 1 These authors contributed equally to the work. ∗ Correspondence to: Dr. Diego Albani, Department of Neuro- science, Mario Negri Institute for Pharmacological Research, Via La Masa 19, 20156 Milan, Italy. Tel.: +39 02 39014594; Fax: +39 02 3546277; E-mail: diego.albani@marionegri.it. ISSN 1387-2877/12/$27.50 © 2012 – IOS Press and the authors. All rights reserved